Biogen Inc.
Revenue
$2B
Net Income
$467M
Biogen Inc.
Revenue
$2B
Net Income
$467M
Biogen Inc.
CIK: 0000875045
Earnings Analysis
Analyzed 11 of 12 reports
Performance Summary - Q3 2025neutral (59)maintained
Reality-Based Sentiment Analysisneutral59/100
Based on actual market data, not just management spin. Weighted score: 10% management tone + 40% earnings beat/miss + 30% price action + 20% guidance accuracy.
Financial Performance Trend
Overall Analysis & Outlook
Over the past 5 quarters, Biogen Inc. has been showing mixed sentiment with stable guidance. Revenue has declined 25% during this period. The latest quarter shows neutral sentiment with cautious tone from management.
Latest Quarter Highlights:
Biogen delivered stable quarterly performance with modest growth in key MS and rare disease franchises. The company continues its strategic restructuring program and is making selective investments in pipeline and AI technologies while managing expenses.
Detailed Quarterly Reports
In-depth analysis of each quarter's earnings filing
Q3 2025
10-Q • Filed 10/30/2025
Summary
Biogen delivered stable quarterly performance with modest growth in key MS and rare disease franchises. The company continues its strategic restructuring program and is making selective investments in pipeline and AI technologies while managing expenses.
Revenue
$1.85B
Net Income
$466.5M
Guidance
Tone
Capex
$109.9M
Partnerships
Key Quotes
"We remain focused on our long-term strategy of discovering and developing innovative therapies for serious and complex diseases."
"Our Fit for Growth program is expected to generate approximately $1.0 billion in gross operating expense savings by the end of 2025."
Q2 2025
10-Q • Filed 7/31/2025
Summary
Biogen delivered stable quarterly performance with modest revenue of $1.88B and net income of $634.8M. The company continues to focus on cost reduction via its Fit for Growth program while making strategic investments in pipeline and emerging technologies.
Revenue
$1.88B
Net Income
$634.8M
Guidance
Tone
Capex
$63.7M
Partnerships
Key Quotes
"We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases"
"The Fit for Growth program is expected to generate approximately $1.0 billion in gross operating expense savings by the end of 2025"
Q1 2025
10-Q • Filed 5/1/2025
Summary
Biogen delivered stable quarterly performance with revenue of $2.43B and net income of $240.5M, reflecting continued focus on cost management through its Fit for Growth program. The company maintains a cautious outlook amid ongoing restructuring and regulatory challenges.
Revenue
$2.43B
Net Income
$240.5M
Guidance
Tone
Capex
$37.1M
Partnerships
Key Quotes
"We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases"
"The Fit for Growth program is expected to generate approximately $1.0 billion in gross operating expense savings by the end of 2025"
Q4 2024
10-K • Filed 2/12/2025
Summary
Biogen faces significant headwinds from generic competition, challenging pricing environment, and ongoing strategic repositioning focused on neurology and specialized immunology.
Revenue
N/A
Net Income
N/A
Guidance
Tone
Partnerships
Key Quotes
"We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases."
"Multiple TECFIDERA generic entrants are now in North America, Brazil and certain European countries and have deeply discounted prices"
Q3 2024
10-Q • Filed 10/30/2024
Summary
Biogen delivered steady quarterly performance with $1.77B in revenue and $388.5M net income. The company continues strategic restructuring efforts through its Fit for Growth program and recently completed the HI-Bio acquisition to strengthen its immunology pipeline.
Revenue
$1.77B
Net Income
$388.5M
Guidance
Tone
Capex
$114.4M
Partnerships
Key Quotes
"We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases."
"The Fit for Growth program is expected to generate approximately $1.0 billion in gross operating expense savings by the end of 2025"
Q2 2024
10-Q • Filed 8/1/2024
Summary
Biogen delivered stable quarterly performance with modest revenue growth. The company continues its cost reduction efforts through the Fit for Growth program while maintaining a diversified portfolio across multiple therapeutic areas.
Revenue
$2.46B
Net Income
$583.6M
Guidance
Tone
Capex
$79.4M
Partnerships
Key Quotes
"We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases."
"The Fit for Growth program is expected to generate approximately $1.0 billion in gross operating expense savings by the end of 2025"
Q1 2024
10-Q • Filed 4/24/2024
Summary
Biogen delivered stable financial performance in Q1 2024, with modest revenue decline offset by cost management efforts. The company continues strategic focus on neurology and rare disease therapies while implementing cost reduction initiatives.
Revenue
$1.71B
Net Income
$393.4M
Guidance
Tone
Capex
$45.9M
Partnerships
Key Quotes
"We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases."
"We initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs"
Q4 2023
10-K • Filed 2/14/2024
Summary
Biogen is experiencing significant revenue pressures from generic competition, particularly for TECFIDERA. The company is exploring strategic options and focusing on new product launches like LEQEMBI and SKYCLARYS while managing manufacturing capacity challenges.
Revenue
$4.47B
Net Income
$1.47B
Guidance
Tone
Capex
$195M
Partnerships
Key Quotes
"We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases."
"The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and we expect that TECFIDERA revenue will continue to decline in the future."
Q3 2023
10-Q • Filed 11/8/2023
Summary
Biogen experienced revenue decline and a quarterly net loss, driven by challenges in multiple sclerosis franchise and ongoing restructuring. The company completed the Reata acquisition, adding Friedreich's Ataxia treatment SKYCLARYS, and continues cost reduction initiatives.
Revenue
$1.81B
Net Income
$-68.1M
Guidance
Tone
Capex
$211.8M
Partnerships
Key Quotes
"We initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness."
"The Fit for Growth program is expected to generate approximately $1.0 billion in gross operating expense savings by 2025"
Q2 2023
10-Q • Filed 7/25/2023
Summary
Biogen experienced revenue and earnings decline driven by MS product weakness. Cost reduction initiatives ongoing, with continued focus on strategic partnerships and new product launches.
Revenue
$2.46B
Net Income
$593.3M
Guidance
Tone
Capex
$137.6M
Partnerships
Key Quotes
"We are focused on advancing our pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases"
"We initiated additional cost saving measures as part of our Fit for Growth initiative"
Q1 2023
10-Q • Filed 4/25/2023
Summary
Biogen delivered a solid Q1 2023 with robust revenue and earnings, driven by continued strength in multiple sclerosis portfolio and new collaboration revenues. The company is managing costs through restructuring and maintaining a confident outlook.
Revenue
$2.46B
Net Income
$387.6M
Guidance
Tone
Capex
$66.6M
Partnerships
Key Quotes
"We are focused on advancing our pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases."
"We collaborate with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease"
Sector Comparison
How BIIB performs vs Healthcare sector and Biotech peers